会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3
    • 具有7-氧和17-杂芳基取代的类固醇-3
    • US20140018337A1
    • 2014-01-16
    • US14027842
    • 2013-09-16
    • Harbor Therapeutics, Inc.
    • James M. Frincke
    • C07J43/00
    • C07J43/003C07J13/005C07J41/0011
    • The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
    • 本发明涉及化合物用于改善或治疗诸如囊性纤维化,中性白细胞减少症或其他示例性病症的病症的用途。 可使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯,3β-羟基-16α-氟-17β-氨基雄甾-5-烯,3α-羟基-16α-氟-17β-氨基雄甾-5-烯 ,3β-羟基-16β-氟-17β-氨基雄甾-5-烯,1α,3β-二羟基-4α-氟代雄甾-5-烯-17-酮,1α,3β,17β-三羟基-4α-氟代雄甾-5-烯 ,1beta,3β-二羟基-6α-溴代雄甾-5-烯,1α-氟-3β,12α-二羟基雄甾-5-烯-17-酮,1α-氟-3β,4α-二羟基雄甾-5-烯和4α-氟 -3β,6α,17β-三羟基雄甾烷。
    • 4. 发明申请
    • Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2
    • 具有7-氧和17-杂芳基取代的类固醇-2
    • US20140018336A1
    • 2014-01-16
    • US14027825
    • 2013-09-16
    • Harbor Therapeutics, Inc.
    • James M. Frincke
    • C07J43/00
    • C07J43/003C07J13/005C07J41/0011
    • The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
    • 本发明涉及化合物用于改善或治疗诸如囊性纤维化,中性白细胞减少症或其他示例性病症的病症的用途。 可以使用的示例性化合物包括3β-羟基-17β-氨基雄甾-5-烯,3β-羟基-16α-氟-17β-氨基雄甾-5-烯,3α-羟基-16α-氟-17β-氨基雄甾-5-烯 ,3β-羟基-16β-氟-17β-氨基雄甾-5-烯,1α,3β-二羟基-4α-氟代雄甾-5-烯-17-酮,1α,3β,17β-三羟基-4α-氟代雄甾-5-烯 ,1beta,3β-二羟基-6α-溴代雄甾-5-烯,1α-氟-3β,12α-二羟基雄甾-5-烯-17-酮,1α-氟-3β,4α-二羟基雄甾-5-烯和4α-氟 -3β,6α,17β-三羟基雄甾烷。